Chimeric Antigen Receptor– tag –
-
FDA Designates Washington University’s WU-CART-007 as Breakthrough Therapy for T-Cell Malignancies: Allogeneic Anti-CD7 CAR T-Cell Therapy Achieves 73% Complete Remission
Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine USA Overview The FDA has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by Washington University Schoo... -
6th mRNA Therapeutics Summit Highlights Shift to Oncology, with In Vivo CAR-T, saRNA, and circRNA as Key Innovations
BioSpace USA Overview The 6th mRNA-Based Therapeutics Summit revealed a significant shift in mRNA clinical activity from infectious diseases to oncology, with in vivo CAR-T emerging as a notable application. Self-amplifying RNA (saRNA) a... -
Allogene Therapeutics’ Off-the-Shelf CAR T Cema-Cel Receives FDA RMAT & Fast Track Designations for First-Line MRD-Positive LBCL, Achieves 58.3% MRD-Negativity in Phase 2 Interim Analysis
Allogene Therapeutics Press Release USA Overview Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel), an off-the-shelf anti-CD19 CAR T-cell therapy, received both Regenerative Medicine Advanced Therapy (RMAT) and ... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro...
1